Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1Lymphoid 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Muscular Atrophy 1Lymphoma, Non-Hodgkin 1ER+ and AR+ Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × ostarine × Clear all
NCT02971761 2024-02-20

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

City of Hope Medical Center

Phase 2 Completed
18 enrolled 17 charts
Breast

Triple Negative Breast Neoplasms

NCT02463032 2020-12-09

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

GTx

Phase 2 Completed
136 enrolled 14 charts
Breast

ER+ and AR+ Breast Cancer

NCT00467844 2014-07-11

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

GTx

Phase 2 Completed
159 enrolled 11 charts
GastrointestinalLymphoidThoracic

Cachexia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Muscular Atrophy, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡